{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:32:55Z","timestamp":1780626775559,"version":"3.54.1"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1069,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p>Thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke often result in long\u2010term disability and\/or mortality. The anticoagulants currently available have been effective in the treatment and prevention of these disorders; however, parenteral administration, variable pharmacokinetics and pharmacodynamics, drug and dietary interactions, and a requirement for frequent monitoring of efficacy and safety limit use of these drugs. Rivaroxaban is a novel, oral factor Xa inhibitor in clinical development for the treatment and prevention of thromboembolic diseases. Rivaroxaban is a small molecule directed at active sites, and the agent mechanistically differs from traditional anticoagulants, such as heparins and fondaparinux, in that its activity is independent of antithrombin and its ability to inhibit prothrombinase bound factor Xa. In addition, preclinical and clinical trial data indicate that rivaroxaban has predictable pharmacokinetics and pharmacodynamics, which are features that differentiate it from oral vitamin K antagonists. Phase II studies showed that rivaroxaban is safe a nd well tolerated across a wide range of doses. Furthermore, completed phase III studies demonstrated its efficacy in the prevention of venous thromboembolism after orthopedic surgery. Additional studies are now under way to evaluate the use of rivaroxaban in the treatment and prevention of other venous and arterial thromboembolic conditions.<\/jats:p>","DOI":"10.1592\/phco.29.2.167","type":"journal-article","created":{"date-parts":[[2009,1,26]],"date-time":"2009-01-26T11:54:27Z","timestamp":1232970867000},"page":"167-181","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor"],"prefix":"10.1002","volume":"29","author":[{"given":"Paris J.","family":"Abrams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0656"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0658"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0691"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0665"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0720"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.139402"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000259363.91070.f1"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.8.843"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm575"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_1_13_2","first-page":"4","volume-title":"Managing oral anticoagulation therapy: clinical and operational guidelines","author":"Goodnight S.H.","year":"2005"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"issue":"11","key":"e_1_2_1_15_2","article-title":"Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study","volume":"110","author":"Kwong L.","year":"2007","journal-title":"Blood (American Society of Hematology annual meeting abstracts)"},{"issue":"11","key":"e_1_2_1_16_2","article-title":"The oral, direct factor Xa inhibitor BAY 59\u20137939 does not cross\u2010react with anti\u2010heparin\/PF4 (heparin\u2010induced thrombocytopenia) antibodies","volume":"106","author":"Walenga J.M.","year":"2005","journal-title":"Blood (American Society of Hematology annual meeting abstracts)"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x"},{"issue":"1","key":"e_1_2_1_18_2","article-title":"Effect of BAY 59\u20137939\u2014a novel, oral, direct factor Xa inhibitor\u2014on clot\u2010bound factor Xa activity in vitro","volume":"3","author":"Depasse F.","year":"2005","journal-title":"J Thromb Haemost"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01166.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.3.1067345"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.8.2308"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00254.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011586200"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250500250493"},{"issue":"1","key":"e_1_2_1_25_2","first-page":"98","article-title":"Metabolism and distribution of [14C] BAY 59\u20137939\u2014an oral, direct factor Xa inhibitor\u2014in rat, dog and human [abstract]","volume":"36","author":"Weinz C.","year":"2004","journal-title":"Drug Metab Rev"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02429.x"},{"issue":"3","key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1160\/TH06-11-0620","article-title":"Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59\u20137939): an oral, direct factor Xa inhibitor","volume":"97","author":"Biemond B.J.","year":"2007","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296058"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286904"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292127"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.642074"},{"issue":"11","key":"e_1_2_1_32_2","article-title":"Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59\u20137939): an oral, direct, factor Xa inhibitor","volume":"108","author":"Halabi A.","year":"2006","journal-title":"Blood (American Society of Hematology annual meeting abstracts)"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02776.x"},{"issue":"6","key":"e_1_2_1_34_2","first-page":"702","article-title":"No interaction between the novel, oral direct factor Xa inhibitor BAY 59\u20137379 and digoxin [abstract]","volume":"46","author":"Kubitza D.","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007302952"},{"issue":"11","key":"e_1_2_1_36_2","article-title":"The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"108","author":"Kubitza D.","year":"2006","journal-title":"Blood (American Society of Hematology annual meeting abstracts)"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.12.025"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01657.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01602.x"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.668020"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160143"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_2_1_45_2","volume-title":"LLC. Lovenox (enoxaparin) package insert","author":"Sanofi\u2010Aventis U.S","year":"2007"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831010-00006"},{"issue":"1","key":"e_1_2_1_47_2","first-page":"98","article-title":"In vitro metabolism of BAY 59\u20137939: an oral, direct factor Xa inhibitor [abstract]","volume":"36","author":"Weinz C.","year":"2004","journal-title":"Drug Metab Rev"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.2.167","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.2.167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:47:39Z","timestamp":1761065259000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.2.167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1592\/phco.29.2.167"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.2.167","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}